Phase 1 Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System Tumors
Latest Information Update: 16 Dec 2024
At a glance
- Drugs EGFR806-specific chimeric antigen receptor CAR-T cell therapy-Cellevolve/ Seattle Childrens Therapeutics (Primary)
- Indications CNS cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BrainChild02
Most Recent Events
- 11 Dec 2024 Status changed from active, no longer recruiting to completed.
- 18 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2022 New trial record